To Perform a Post-market Study of the Performance of the Idylla ThyroidPrint Assay Using Clinical Samples in Predicting the Nature of Indeterminate Thyroid Nodules (ITNs) Across Multiple Centers.
Idylla™ ThyroidPrint® RUO Assay Beta-Trial Study
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
This is a multicenter, non-interventional (observational), prospective, post-market study, matching the Idylla™ ThyroidPrint® RUO Assay result to the gold standard of surgical pathology.
The study population is defined as cases where the thyroid nodule has been reported as indeterminate.
Primary endpoints are the calculation of the sensitivity, specificity, and the negative and positive predictive values of the Idylla™ ThyroidPrint® RUO Assay for indeterminate thyroid nodules.
Secondary endpoint: to assess the failure rate of Idylla™ ThyroidPrint® RUO Assay, including errors and invalids; describe the nature of false negative and false positive cases.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Verity Teague Research Sponsorship Facilitator
- Phone Number: 0044 1872256429
- Email: rcht.sponsor@nhs.net
Study Locations
-
-
Cornwall
-
Truro, Cornwall, United Kingdom, TR1 3HD
- Recruiting
- Royal Cornwall Hospital
-
Contact:
- Verity Teague
- Phone Number: 01872256429
- Email: rcht.sponsor@nhs.net
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Thyroid nodule ≥1.0 cm
- With indeterminate cytology
- Surgery due to be performed
Exclusion Criteria:
- Specimens which fail to meet the inclusion criteria.
- FNA fixed in formalin or transferred in alcohol-based collection buffers which is not according to the protocol instructions.
- RNA extracts.
- Patients with ultrasound evidence of malignant cervical adenopathy
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Primary endpoints
Time Frame: Samples taken at Baseline
|
to measure the accuracy of the Thyroid print test against the surgical pathology report.
|
Samples taken at Baseline
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2425.RCHT.12
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.